Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Tesaro Rose 60.6% in November -- and Another 60% Since

By Maxx Chatsko - Dec 10, 2018 at 1:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Rumors of an acquisition swirled last month before being proven as fact in December.

What happened

Shares of Tesaro (NASDAQ: TSRO) jumped over 60% last month, and another 60% since the beginning of December, according to data provided by S&P Global Market Intelligence. Investors grew excited over rumors that the biopharma company was in acquisition talks. Those rumors were confirmed on Dec. 3 when GlaxoSmithKline ( GSK 0.61% ) announced it was gobbling up the struggling biopharma for a cool $5.9 billion (including debt). As far as investors are concerned, that works out to $75 per share.

Believe it or not, despite gaining 156% since the beginning of November, shares of Tesaro are still down 11% since the beginning of 2018. That's because the company has struggled to impress with Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, in approved indications. It also appears to be falling behind peers in the footrace for the multibillion-dollar opportunities that are expected from expanded approvals for the drug class. Can GlaxoSmithKline change the minds of investors?

An arrow bounces up shelves on a wall.

Image source: Getty Images.

So what

There are currently three major PARP inhibitors on the market for treating late-stage cancers: olaparib (Lynparza) from Merck and AstraZeneca, rucaparib (Rubraca) from Clovis Oncology, and niraparib (Zejula). All three drugs treat types of ovarian cancer that have BRCA mutations, but the market for third- and fourth-line therapies is limited. That's why investors are so excited about the potential for the drug class to become first-line treatment options for BRCA-mutated cancers, namely breast cancer, ovarian cancer, and prostate cancer.

Lynparza recently released pretty impressive data demonstrating its ability to treat ovarian cancer, which led many analysts to declare the race for that multibillion-dollar bounty all but over. Meanwhile, Rubraca has shown strong results from its clinical trials in prostate cancer, which could help it become the first to earn approval as an early-stage treatment option in that indication. Zejula, on the other hand, is behind in both races and hasn't yet come close to living up to its market potential.

Now what

GlaxoSmithKline is apparently betting that it can use its deep financial resources and marketing know-how to help Zejula compete more effectively. It may be right, especially if Zejula can steal market share from other PARP inhibitors even if they gain marketing approval first. Considering that Lynparza is owned by two pharma heavyweights, it may take another titan to compete at all. Investors will have to wait for more data to know for sure, but the PARP inhibitor will now be only a small part of the company's portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$41.37 (0.61%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.